Investors Eye Class Action Against Disc Medicine Following FDA Setback

The regulatory hurdle emerged when the U.S. Food and Drug Administration issued a Complete Response Letter regarding the company’s new drug application. The agency cited significant uncertainties within the filing, noting that the existing data was insufficient to support approval of the bitopertin program. This disclosure prompted a sharp sell-off, erasing nearly a quarter of the company's market value in a single session.

Rosen Law is now soliciting inquiries from affected shareholders to determine the viability of a class action suit. The firm operates on a contingency fee basis, meaning participants are not required to cover out-of-pocket legal expenses. Investors who acquired Disc Medicine securities before the mid-February decline are encouraged to contact attorney Phillip Kim to discuss their potential recovery options.